Gemini Therapeutics

@gemini_thera

Pursuing the promise of precision medicine in AMD and associated rare genetic diseases

Vrijeme pridruživanja: rujan 2017.

Tweetovi

Blokirali ste korisnika/cu @gemini_thera

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @gemini_thera

  1. 9. sij

    We have enrolled the first patient in a Phase 1 study of GEM103 for dry AMD, enrolling patients with high-risk genetic variants in CFH. A big step in our mission to combine precision medicine and leading genetic insights in

    Poništi
  2. 13. ruj 2019.

    We’re excited to announce the appointment of Jason Meyenburg, MBA, as Gemini’s Chief Executive Officer. Welcome, Jason!

    Poništi
  3. 7. sij 2019.

    Today, we're announcing the initiation of CLARITY, a disease registry and natural history study of subjects with dry AMD and high-risk genotypes. Learn more about CLARITY:

    Poništi
  4. 27. stu 2018.

    We’re pleased to announce that Gemini CEO James McLaughlin will present a company overview today at ’s 30thAnnual Healthcare Conference in New York City. Additional details here:

    Poništi
  5. 25. lis 2018.

    Today, we’re pleased to share that Gemini CEO James McLaughlin is in Chicago providing a company overview at the 2018 Ophthalmology Innovation Summit. Read more here:

    Poništi
  6. 25. ruj 2018.

    Diverse expertise, singular vision: Our team, founders and SAB bridge the diverse specialties necessary to bring precision medicine to . Learn more about our industry leaders:

    Poništi
  7. 18. ruj 2018.

    We're focused on solutions for patients--not a single technology. Learn more about our vision:

    Poništi
  8. 13. ruj 2018.

    There are two types of AMD: wet and dry. Do you know the difference? Learn more on website:

    Poništi
  9. 13. ruj 2018.

    Dry AMD: “We believe that genetics plays a key role, and we’re spending a lot of time trying to understand these subpopulations,”- James McLaughlin, Gemini CEO. Read more about Gemini's unique approach in the and the rising prevalence in .

    Poništi
  10. 12. ruj 2018.

    Congrats to all of the finalists last week at the and to our CEO, James McLaughlin for winning the Young Innovator category!

    Poništi
  11. proslijedio/la je Tweet
    8. kol 2018.
    Poništi
  12. 28. kol 2018.

    We're not limited to a single approach. We have selected a range of technologies that are suited for each of our targets.

    Poništi
  13. 22. kol 2018.

    We are more than a drug development company: we are working to define and differentiate high-risk, genetically-defined subpopulations. By zeroing in the specific genetic risk factors, we can help a broad range of associated conditions. Learn more:

    Poništi
  14. 14. kol 2018.

    Our patient perspective keeps us inspired and commited to developing first-in class therapeutic agents for AMD and associated systemtic diseases. Keep up to date with our targets and projects:

    Poništi
  15. 7. kol 2018.

    We are partnered with leading academic institutions and corporate innovators, such as , Sanquin and Stride Bio. Learn more about our partners:

    Poništi
  16. 3. kol 2018.

    Are you looking to dive deep into retinal research? We're hiring an associate scientist, retina biology. Details here:

    Poništi
  17. 26. lip 2018.

    How does affect vision? Check out our vision simulator:

    Poništi
  18. 19. lip 2018.

    ICYMI: We welcomed two new members to our team and promoted our SVP for process development and manufacturing to CTO. Learn more about Claude, Sandra and Scott:

    Poništi
  19. 14. lip 2018.

    We're seeking a Senior Clinical Program Manager who has a strong sense of initiative to lead trial implementation teams and manage clinical operations. Follow the link to learn more:

    Poništi
  20. 14. lip 2018.

    Do you have experience in cell culture and biochemical assay techniques like Western blot, ELISA and PCR? We're seeking a talented scientist to join our retina biology group. Follow the link to learn more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·